Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME LANDMAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1346204690
CMS profile
105508
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$290.90

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $290.90 12

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $123.34 6
Teva Pharmaceuticals USA, Inc. $98.51 2
PFIZER INC. $69.05 4

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME LANDMAN

NPI 1346204690 · CMS profile ID 105508

Allopathic & Osteopathic Physicians / Allergy & Immunology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $290.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.5011/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673645453 CMS
GlaxoSmithKline, LLC. $17.9811/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671452985 CMS
PFIZER INC. $17.0010/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673308605 CMS
PFIZER INC. $11.3508/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673271345 CMS
PFIZER INC. $23.2007/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673263469 CMS
GlaxoSmithKline, LLC. $16.9406/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671371539 CMS
GlaxoSmithKline, LLC. $24.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670576149 CMS
Teva Pharmaceuticals USA, Inc. $70.4905/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697805199 CMS
Teva Pharmaceuticals USA, Inc. $28.0205/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697707737 CMS
GlaxoSmithKline, LLC. $20.5204/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671487659 CMS
GlaxoSmithKline, LLC. $20.5202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670670245 CMS
GlaxoSmithKline, LLC. $22.5201/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670938407 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $290.90 12
PY2020 $140.24 7
PY2021 $151.53 7
PY2022 $161.81 7
PY2023 $108.04 5
PY2025 $185.24 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $751,515.35 131
PY2024 Principal investigator $525,143.48 126
PY2023 Principal investigator $497,961.58 102
PY2022 Principal investigator $447,451.34 86
PY2021 Principal investigator $586,667.15 102
PY2020 Recipient $11,702.26 1
PY2020 Principal investigator $473,131.41 28
PY2019 Recipient $1,525.00 1
PY2019 Principal investigator $615,806.88 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,968.21 12/31/2019 Non-covered Recipient Entity
Florida Ctr For Allergy And Asthma
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684980723
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,650.00 12/19/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023347
Recipient Eli Lilly and Company $1,525.00 11/21/2019 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 654282733
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,650.00 11/18/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023337
Principal investigator 1 Eli Lilly and Company $107.46 11/12/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 654290849
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,960.00 10/15/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685023327
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,180.00 09/18/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685020713
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33,750.00 08/22/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685020703
Principal investigator 1 GlaxoSmithKline, LLC. $9,086.97 08/20/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669957375
Principal investigator 1 GlaxoSmithKline, LLC. $14,673.49 08/20/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669959259
Principal investigator 1 GlaxoSmithKline, LLC. $559.00 08/20/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669959261
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,617.60 08/06/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685025169
Principal investigator 1 GlaxoSmithKline, LLC. $7,951.79 07/29/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669959611
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,000.00 07/16/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685020693
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,970.00 06/24/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018995
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 06/18/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008349
Principal investigator 1 GlaxoSmithKline, LLC. $35,732.88 06/17/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669957923
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $345.60 05/29/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008355
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,690.00 05/14/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018989
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $464.00 05/07/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008363
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,500.00 05/02/2019 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 685018983
Principal investigator 1 GlaxoSmithKline, LLC. $1,825.00 04/23/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669958893
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,675.00 04/23/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008367
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $100.00 04/23/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008371
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $464.00 04/23/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008377
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $352.37 04/19/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685027039
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/18/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669956307
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.75 04/18/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669972817
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $345.65 04/18/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685026883
Principal investigator 1 GlaxoSmithKline, LLC. $3,150.00 04/11/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669958251
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $314.37 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685026892
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $246.00 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685026897
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $354.82 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685026905
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $314.37 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685027047
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $246.00 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685027055
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $354.82 04/10/2019 Non-covered Recipient Individual CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 685027071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $256.00 04/09/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008357
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,229.40 04/09/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685008381
Principal investigator 1 GlaxoSmithKline, LLC. $6,232.50 03/29/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669958967
Principal investigator 1 CHIESI USA, INC. $1,050.00 03/28/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH CORPORATION
CCD-05993AA3-01 No dispute reported 06/30/2026 700958581
Principal investigator 1 CHIESI USA, INC. $825.00 03/28/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH CORPORATION
CCD-05993AA3-01 No dispute reported 06/30/2026 700958681
Principal investigator 1 CHIESI USA, INC. $1,000.00 03/27/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH CORPORATION
CCD-05993AA3-01 No dispute reported 06/30/2026 700958679
Principal investigator 1 GlaxoSmithKline, LLC. $702.00 03/27/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669971931
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 03/13/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669971629
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,499.20 03/12/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006875
Principal investigator 1 GlaxoSmithKline, LLC. $2,989.82 03/07/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669956061
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,155.00 03/04/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA No dispute reported 06/30/2026 640716315
Principal investigator 1 GlaxoSmithKline, LLC. $7,492.05 02/15/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669956597
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,407.00 02/12/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006879
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $256.00 02/12/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006885
Principal investigator 1 GlaxoSmithKline, LLC. $10,179.00 02/11/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669953941
Principal investigator 1 GlaxoSmithKline, LLC. $10,933.00 01/30/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669953827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $256.00 01/29/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006883
Principal investigator 1 GlaxoSmithKline, LLC. $2,100.00 01/24/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669955795
Principal investigator 1 AstraZeneca Pharmaceuticals LP $105,443.46 01/22/2019 Non-covered Recipient Entity
Florida Ctr For Allergy And Asthma
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684980717
Principal investigator 1 CHIESI USA, INC. $4,822.50 01/19/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH CORPORATION
CCD-05993AA3-01 No dispute reported 06/30/2026 700958579
Principal investigator 1 GlaxoSmithKline, LLC. $25,516.83 01/17/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
AN OPEN LABEL, RANDOMISED, PARALLEL GROUP CLINICAL STUDY TO EVALUATE T No dispute reported 06/30/2026 669953883
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,121.00 01/15/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006877
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $256.00 01/08/2019 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma No dispute reported 06/30/2026 685006881
Principal investigator 1 Novartis Pharmaceuticals Corporation $61,166.97 01/01/2019 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD OF CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 640716319